Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate

Executive Summary

Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.

Advertisement

Related Content

KKR Steers Nature's Bounty With Carlyle In Back Seat After Seven-Year Ride
Biopharma Quarterly Dealmaking Statistics, Q4 2016
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
Capsugel Flexes Breadth Of Capabilities In Development Collaborations
Capsugel CEO Driesen Plots Post-Pfizer Course

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel